Company Overview
Fulgent Genetics, Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry by providing clinical diagnostic and therapeutic development solutions to physicians and patients both domestically and internationally. The company's core business encompasses a range of clinical diagnostic solutions that include molecular diagnostic testing, genetic testing, and anatomic pathology laboratory tests designed to support patient care and research initiatives. As of the latest available data, the company maintains a market capitalization of $520.61M and generates annual revenue of $322.67M based on trailing twelve-month figures. These financial metrics indicate that Fulgent Genetics is a mid-sized entity within the broader diagnostics landscape, employing a workforce of 1315 individuals to deliver its services across the United States and international markets.
Financial Health
The company reported a revenue of $322.67M over the trailing twelve months, yet this generated a net income of $-60,513,000 and an EBITDA of $-65,049,000, revealing a significant gap between top-line growth and profitability that highlights substantial operating costs and investments in expansion. This negative earnings position is further underscored by a free cash flow of $-121,573,376, which indicates that the company is currently burning cash rather than generating liquidity, suggesting limited financial flexibility for discretionary spending without external capital infusion. Despite these losses, the company holds a robust cash reserve of $336.08M against a relatively low debt level of $8.04M, resulting in a debt-to-equity ratio of 0.73 that suggests a balance sheet is heavily weighted toward cash assets rather than leverage. The margin profile reflects this financial structure, with a gross margin of 40.6% indicating favorable pricing or cost control on direct goods, while an operating margin of -41.2% and a profit margin of -18.8% demonstrate significant overhead burdens relative to revenue. Liquidity is exceptionally strong, evidenced by a current ratio of 6.48, which implies the company possesses more than six times the current assets needed to cover its short-term liabilities. Finally, the return metrics show a return on equity of -5.5% and a return on assets of -4.6%, revealing that management is currently deploying capital to generate losses rather than positive returns, a common characteristic in growth-stage biotechnology firms.
Valuation Assessment
Valuation multiples for Fulgent Genetics reflect its unprofitable status, with a trailing P/E ratio listed as N/A and a forward P/E of -11.23, implying that the market prices the stock based on future earnings expectations rather than current profitability. The price-to-book ratio stands at 0.47, indicating that the market values the company at less than half of its tangible book value, which suggests a discount applied to the firm's net asset position. Alternative valuation metrics such as a price-to-sales ratio of 1.61 and an EV/EBITDA of -2.88 provide further context, showing that investors are paying a premium relative to sales despite the negative earnings yield. In terms of trading range, the stock has a 52-week high of $31.04 and a 52-week low of $13.46; assuming the current trading environment places the price near the lower end of this historical range, the security trades significantly below its recent peak. The beta value of 0.95 indicates that the stock's price volatility moves in tandem with the broader market, lacking significant defensive or aggressive characteristics relative to the general index.
Growth & Income
Revenue growth for the company is recorded at 9.3% year-over-year, while earnings growth is N/A due to the absence of positive net income, meaning the company is currently prioritizing revenue expansion over immediate profitability. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash flows are being retained and reinvested into the business rather than distributed to shareholders. The absence of a dividend program aligns with the negative net income and negative free cash flow, as the organization requires internal capital retention to fund its operations and strategic initiatives. Overall, the growth and income profile characterizes Fulgent Genetics as a high-revenue-growth entity that currently sacrifices shareholder income to sustain negative earnings and fund operational scaling.